Phase I data for the Twinstrand drug TST10088 to be presented at International Cancer Therapeutics Conference

    BURNABY, BC, Oct. 1 /CNW/ - Twinstrand Therapeutics Inc. today announced
that an abstract entitled, "Phase I study of the ribosome inactivating protein
prodrug TST10088 (TST88) in patients with advanced solid tumors", has been
accepted for presentation at the Molecular Targets and Cancer Therapeutics
International Conference to be held in San Francisco, California on
October 22-26, 2007. A poster presentation of clinical data (abstract number
B149) will be given on October 24, 2007 by clinical investigators Ignacio
Duran and Lillian Siu, from the Princess Margaret Hospital (Toronto, ON) and
Lia Gore, S. Gail Eckhardt and Stephen Leong from the University of Colorado
Cancer Center (Aurora, CO).
    Investigators will present data concerned with the safety, tolerability
and preliminary activity of TST10088 in a dose escalating study of 27 patients
with advanced solid tumors who had failed prior treatments. Twinstrand is now
completing the Phase I safety study with plans to begin Phase II studies of
TST10088 in Hormone Refractory Prostate Cancer and Ovarian Cancer in 2008.
    The Molecular Targets and Cancer Therapeutics International Conference is
held annually and sponsored by the American Association for Cancer Research
(AACR), the National Cancer Institute (NCI) and the European Organisation for
Research and Treatment of Cancer (EORTC).

    About Twinstrand - Twinstrand is a private clinical-stage
biopharmaceutical company dedicated to the discovery and development of
biological drugs for the treatment of life threatening diseases. Established
in 1995, the company has offices and laboratories in Burnaby, British
Columbia, Canada.
    Twinstrand's platform is based on a unique 'prodrug' targeting concept
that is able to discriminate between healthy and diseased cells by the
differential expression of certain proteases in these tissues. Research is
currently focused on the development of drugs for the treatment of cancer. In
addition, the Company has ownership of a platform with broad potential in the
treatment of diseases including, but not limited to; hepatitis C, HIV/AIDS,
hepatitis A, cytomegalovirus, parasitic infections such as malaria and
schistosomiasis, and fungal diseases.

    About TST10088 - TST10088 is a recombinant protein-based prodrug that
Twinstrand has engineered for activation by matrix metalloproteinases (MMPs)
associated with solid tumor forms of cancer. Once the prodrug is activated it
kills tumor cells by a catalytic mechanism involving the inactivation of
ribosomes and induction of apoptosis.

For further information:

For further information: please visit our website at
or contact Marjorie Co at or at (604) 415-7180

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890